Drug intelligence / Profile preview

OST-AXLA

Development stage: Preclinical
Lead developer: OS Therapies
Modality: Vaccines & Immunotherapeutics

Overview

OST-AXLA is a listeria-based (Lm) immunotherapy asset initially developed by Advaxis. It was subsequently licensed and later fully acquired by OS Therapies. The drug is being developed for the treatment of HPV-related cancers, leveraging a modified *Listeria monocytogenes* bacterium to elicit an immune response against cancer cells associated with Human Papillomavirus.

Beyond the preview

Go deeper on OST-AXLA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OST-AXLA.

Explore the full profile